title: Vasodilatory Shock After Ventricular Assist Device Placement: A Bench to Bedside Review.
abstract: With more than 2000 ventricular assist devices (VAD) placed annually in the United States, understanding postoperative management is important. One of the most common postoperative morbidities encountered with VAD implantation is vasodilatory shock. The mechanisms for this phenomenon are numerous and include cellular and hormonal aberrancies unique to the VAD recipient. Management of vasodilatory shock in VAD patients needs to be undertaken with an understanding of the side effects associated with each treatment, especially the effects on the right ventricle and pulmonary vasculature. This article focuses on the incidence, the pathogenesis, the consequences, and the management of vasodilatory shock in the postoperative VAD patient.
authors.affiliation: Department of Anesthesiology, University of Kansas Medical Center, Kansas City, Kansas.
authors.forename: John
authors.initials: J
authors.lastname: Baer
authors.affiliation: Department of Anesthesiology and Critical Care, University of Kansas Medical Center, Kansas City, Kansas.
authors.forename: Shea
authors.initials: S
authors.lastname: Stoops
authors.affiliation: Department of Anesthesiology and Critical Care, University of Kansas Medical Center, Kansas City, Kansas.
authors.forename: Brigid
authors.initials: B
authors.lastname: Flynn
mesh_terms: D000818:Animals; D006333:Heart Failure / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D006353:Heart-Assist Devices / Q000009:adverse effects*; D006801:Humans; D054086:KATP Channels / Q000378:metabolism; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology*; D009481:Neurophysins / Q000378:metabolism; D009569:Nitric Oxide / Q000378:metabolism; D011474:Prosthesis Design; D011498:Protein Precursors / Q000378:metabolism; D012307:Risk Factors; D012769:Shock / Q000175:diagnosis / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy; D016896:Treatment Outcome; D014662:Vasoconstrictor Agents / Q000627:therapeutic use; D014664:Vasodilation / Q000187:drug effects; D014667:Vasopressins / Q000378:metabolism; D016276:Ventricular Function
chemical_list: C438657:AVP protein, human; D054086:KATP Channels; D009481:Neurophysins; D011498:Protein Precursors; D014662:Vasoconstrictor Agents; D014667:Vasopressins; D009569:Nitric Oxide
keywords: vasodilatory shock; vasopressin; ventricular assist device